Shares of Health Care sector company Sarepta Therapeutics moved 2.3% today, and are now trading at a price of $140.49. The Large-Cap stock's daily volume was 1,370,595 compared to its average volume of 1,958,719. The S&P 500 index returned a -0.0% performance.
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. The company is based in Cambridge and has 1,314 full time employees. Its market capitalization is $13,398,012,928.
19 analysts are following Sarepta Therapeutics and have set target prices ranging from $110.0 to $220.0 per share. On average, they have given the company a rating of buy. At today's prices, SRPT is trading -25.56% away from its average analyst target price of $188.73 per share.
Over the last year, SRPT's share price has increased by 22.7%, which represents a difference of -3.4% when compared to the S&P 500. The stock's 52 week high is $173.25 per share whereas its 52 week low is $55.25. Sarepta Therapeutics has averaged free cash flows of $-392596333.3 over the last 5 years, with a mean growth rate of -3.6%. It is unlikely that the stock can sustain its current performance trend for the long term when the underlying business is experiencing such poor cash flows.
| Date Reported | Cash Flow from Operations ($ k) | Capital expenditures ($ k) | Free Cash Flow ($ k) | YoY Growth (%) |
|---|---|---|---|---|
| 2023 | -500,993 | 76,106 | -577,099 | -62.03 |
| 2022 | -325,346 | 30,824 | -356,170 | 26.05 |
| 2021 | -443,172 | 38,490 | -481,662 | -2006.52 |
| 2020 | 107,466 | 82,202 | 25,264 | 104.9 |
| 2019 | -456,463 | 59,631 | -516,094 | -14.73 |
| 2018 | -388,660 | 61,157 | -449,817 |
